Stryker Corporation (SYK)
NYSE: SYKHealthcareMedical DevicesUSD
Market open · Delayed 15 min · as of Oct 7, 3:31 PM ET
SYK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $105.80B
- P/E (TTM)
- 28.58
- Forward P/E
- 16.51
- EPS (TTM)
- $9.65
- Dividend yield
- 1.26% ($3.48)
- Ex-dividend date
- Sep 30, 2026
- 52-week range
- 267.00 – 392.55
- Day range
- 274.45 – 281.96
- Volume / Avg
- 1.26M / 2.63M
- Beta
- —
- Shares outstanding
- 383.57M
- Next earnings
- Oct 29, 2026
52-week range
SYK stock today
Stryker (SYK) is trading at $275.82 on Oct 7, down 0.86% (-$2.39), versus the S&P 500's 0.25% decline. Shares are 29.7% below their 52-week high of $392.55, set on Oct 22, 2025 and 3.3% above the 52-week low of $267.00, near the bottom of the past year's range. SYK is down 20.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 24.7%.
At 28.6x trailing earnings, Stryker trades above the peer-group median of 23.4x. Its forward P/E of 16.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Stryker's next earnings report is expected on Oct 29, 2026. Stryker pays an annual dividend of $3.48 per share, a 1.26% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Stryker
Company profileStryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Kevin A. Lobo
- Headquarters
- Portage, MI
- Employees
- 56,000
- Website
- stryker.com
Financial highlights
Full financialsIn fiscal 2025, Stryker generated $25.12 billion in revenue, up 11.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $3.25 billion (+8.5% year over year), for a net margin of 12.9% versus a median of 12.8% in the prior 5 years. Gross margin was 64.0% (up from 63.9%) and operating margin 19.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $25.12B | $22.59B | $20.50B | $18.45B | $17.11B |
| Growth | +11.16% | +10.23% | +11.11% | +7.84% | +19.21% |
| Net income | $3.25B | $2.99B | $3.17B | $2.36B | $1.99B |
| EPS (diluted) | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 |
Analyst forecast
ForecastConsensus (29 analysts)
buy
Avg. price target
$366.15+32.75%
- Strong buy 8
- Buy 15
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $3.60
- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $3.30 vs —
Dividends
Dividend history- Annual dividend
- $3.48
- Dividend yield
- 1.26%
- Last payment
- $0.88
- Ex-dividend date
- Sep 30, 2026
SYK news
All SYK news- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaABT, BCS, SYK
- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaSYK, BLSH, BCS
- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaSYK, BCS
- Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?NasdaqJNJ, BSX, MDT, SYK
- Stryker, Neogenomics Announce CEO Transitions; Both Stocks DiveInvestor's Business DailyNEO, SYK
- Stryker: This Dividend Aristocrat Is Finally Cheap AgainSeeking Alpha
- GEHC vs. SYK: Which Stock Should Value Investors Buy Now?NasdaqGEHC, SYK
- Stryker Now #115 Largest Company, Surpassing Vertiv HoldingsNasdaqSYK, VRT
Stryker peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MDTMedtronic plc. | 85.62 | -1.69% | $109.52B | vs SYK |
| BSXBoston Scientific Corporation | 41.55 | -1.52% | $60.22B | vs SYK |
| EWEdwards Lifesciences Corporation | 85.72 | -0.88% | $49.41B | vs SYK |
| ABTAbbott Laboratories | 98.60 | +0.44% | $170.61B | vs SYK |
| DXCMDexCom Inc. | 84.06 | +0.80% | $31.72B | vs SYK |
| GEHCGE HealthCare Technologies Inc. | 64.72 | -0.08% | $29.23B | vs SYK |
| PHGKoninklijke Philips N.V. NY Registry Shares | 24.04 | -0.48% | $23.49B | vs SYK |
| STESTERIS plc (Ireland) | 210.31 | +0.79% | $20.50B | vs SYK |
Indexes, lists and sector
Index membership
Appears in lists
Stryker stock FAQ
What is Stryker's stock price today?
SYK last traded at $275.82 as of Oct 7, 3:31 PM EDT, down 0.86% on the day. Prices are delayed at least 15 minutes.
Does Stryker pay a dividend?
Yes. Stryker pays $3.48 per share annually, a 1.26% yield. The most recent dividend of $0.88 had an ex-dividend date of Sep 30, 2026.
When is Stryker's next earnings date?
Stryker is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $3.60.
What is SYK's P/E ratio?
SYK trades at a trailing P/E ratio of 28.58 and a forward P/E of 16.51, compared with a median of 23.4 for its closest peers.
Is Stryker in the S&P 500?
Yes. Stryker (SYK) is a constituent of the S&P 500 index.
Who is Stryker's CEO?
Mr. Kevin A. Lobo is the chief executive officer of Stryker Corporation, which has about 56,000 employees.
Has SYK ever split its stock?
Yes. The most recent SYK stock split was a 2-for-1 split on May 17, 2004, one of 9 splits on record.